ESC 365 - Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.

ESC Professional Premium Access

Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.

Session: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor E. Stroes (Amsterdam, NL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))

39 presentations

0 follower

4 more presentations in this session

Residual inflammatory risk.

Speaker: Professor W. Koenig (Munich, DE)

Residual thrombotic risk: from monotherapy to dual pathway inhibition.

Speaker: Professor B. Rocca (Casamassima, IT)

Residual diabetic risk: from glucose lowering to cardiovascular protection.

Speaker: Professor N. Marx (Aachen, DE)

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.

Access the full session

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Speakers: Professor E. Stroes, Professor W. Koenig, Professor B. Rocca, Professor N. Marx

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources